Heron Therapeutics | HRTX - Capitale Ordinario





Capitale Ordinario Cambiamento Data
ALKERMES USD 167.54M 1.08M 2026-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amarin USD 20.81M 13K 2025-12
ANI Pharmaceuticals USD 22.49M 760K 2025-12
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
Eisai JPY 282.46M 345K 2026-06
Emergent BioSolutions USD 100K 0 2023-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 218.28M 1.76M 2026-06
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 4.93M 2026-03
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Omeros USD 611K 17K 2023-12
Pacira USD 39.82M 512K 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Veracyte USD 79.79M 1000 2026-06
Vertex Pharmaceuticals USD 253.3M 900K 2026-06